Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors

Future Oncology

Volumn 3, Issue 3, 2007, Pages 277-283

  Rosell, Rafael ^a   Taron, Miguel ^a   Sanchez, Jose Javier ^b   Paz Ares, Luis ^c  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; LEUCINE; PACLITAXEL;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DNA METHYLATION; DRUG RESPONSE; DRUG SENSITIVITY; ETHNIC DIFFERENCE; EXON; GENE AMPLIFICATION; GENE DELETION; GENE OVEREXPRESSION; HUMAN; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; PHARMACOGENETICS; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; SURVIVAL TIME;

BRONCHOSCOPY; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34347368906     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.3.3.277     Document Type: Article

References (53)

1. Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341-354 (2005).
2. Endoh H, Yatabe Y, Kosaka T et al.: PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J. Thorac. Oncol. 1, 629-634 (2006).
3. Uchida A, Hirano S, Kitao H et al.: Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Sci. 98, 357-363 (2007).
4. Engelman JA. Mukohara T, Zejnullahu K et al.: Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Invest. 116, 2695-2706 (2006).
5. Lynch TJ, Bell DW, Sordella R et al.: Activating mutations in die epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
6. Paez JG, Janne PA, Lee JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
7. Pao W, Miller V, Zakowski M et al.: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306-13311 (2004).
8. Fukuoka M, Yano S, Giaccone G et al.: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 21, 2237-2246 (2003).
9. Kris MG, Natale RB, Herbst RS et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149-2158 (2003).
10. Mitsudomi T, Kosaka T, Yatabe Y: Biological and clinical implications of EGFR mutations in lung cancer. Int. J. Clin. Oncol. 11, 190-198 (2006).
11. Uramoto H, Mitsudomi T: Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br. J. Cancer 96, 857-863 (2007).
12. Rosell R, Ichinose Y, Taron M et al.: Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer 50, 25-33 (2005).
13. Taron M, Ichinose Y, Rosell R et al.: Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin. Cancer Res. 11, 5878-5885 (2005).
14. Cortes-Funes H, Gomez C, Roscel R et al.: Epidermal growdi factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann. Oncol. 16, 1081-1086 (2005).
15. Sharma SV, Bell DW, Settleman J et al.: Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169-181 (2007).
16. Bell DW, Lynch TJ, Haserlac SM et al.: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 23, 8081-8092 (2005).
17. Giaccone G, Herbst RS, Manegold C et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 1. J. Clin. Oncol. 22, 777-784 (2004).
18. Herbst RS, Giaccone G, Schiller JH et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 2. J Clin. Oncol. 22, 785-794 (2004).
19. Herbst RS, Prager D, Hermann R et al.: TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23, 5892-5899 (2005).
20. Rosell R, Taron M, Reguart N et al.: Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. Clin. Cancer Res. 12, 7222-7231 (2006).
21. Yacoub A, McKinstry R, Hinman D et al.: Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat. Res. 159, 439-452 (2003).
22. Li Q, Gardner K, Zhang L et al.: Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J. Biol. Chem. 273, 23419-23425 (1998).
23. Cunningham D, Humbler Y, Siena S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004).
24. Lord RV, Brabender J, Gandara D et al.: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 8, 2286-2291 (2002).
25. Rosell R, Danenberg KD, Alberola V et al.: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/ cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 10, 1318-1325 (2004).
26. Cobo M, Isla D, Massuti B et al.: Customizing cisplatin-based chemotherapy on quanticative excision repair cross-complementing 1 mRNA expression: a Phase III randomized trial in non-small-cell lung cancer. J. Clin. Oncol. (2007) (In Press).
27. Itay T, Yamaoto N, Ando M et al.: Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer. Cancer Sci. 98, 226-230 (2007).
28. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005).
29. Thatcher N, Chang A, Parikh P et al.: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, 1527-1537 (2005).
30. Samuels Y, Wang Z, Bardelli A et al.: High firequenq of mutations ofthe PIK3CA gene in human cancers. Science 304, 554 (2004).
31. Santarpia M, Altavilla G, Salazar F et al.: From the bench to the bed: individualizing treatment in non-small-cell lung cancer. Clin. Transl. Oncol. 8, 71-76 (2006).
32. Yun CH, Boggon TJ, Li Y et al.: Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11, 217-227 (2007).
33. Carey KD, Garton AJ, Romero MS et al.: Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 66, 8163-8171 (2006).
34. Mitsudomi T, Kosaka T, Endoh H et al.: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23, 2513-2520 (2005).
35. Riely GJ, Pao W, Pham D et al.: Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 12, 839-844 (2006).
36. Jackman DM, Yeap BY, Sequist LV et al.: Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin. Cancer Res. 12, 3908-3914 (2006).
37. Okabe T, Okamoto I, Tamura K et al.: Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res. 67, 2046-2053 (2007).
38. Inoue A, Suzuki T, Fukuhara T et al.: Prospective Phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J. Clin. Oncol. 24, 3340-3346 (2006).
39. Paz-Ares L, Sanchez JM, Garcia-Velasco A et al.: A prospective Phase II trial of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J. Clin. Oncol. 24, S369 (Abstract 7020) (2006).
40. Kimura H, Kasahara K, Kawaishi M et al.: Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin. Cancer Res. 12, 3915-3921 (2006).
41. Queralt C, Mayo C, Pradas A et al.: High correspondence between EGFR mutations in tissue and in circulating DNA from non-small-cell lung cancer (NSCLC) patients (p) with poor performance status (PS). Presented at: American Association for Cancer Research Annual Meeting. Los Angeles, CA, USA, April 14-18, 2007.
42. Ramirez JL, Rosell R, Taron M et al.: 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. J. Clin. Oncol. 23, 9105-9112 (2005).
43. Kobayashi S, Boggon TJ, Dayaram T et al.: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792 (2005).
44. Pao W, Miller VA, Politi KA et al.: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).
45. Kwak EL, Sordella R, Bell DW et al.: Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA 102, 7665-7670 (2005).
46. Kosaka T, Yatabe Y, Endoh H et al.: Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res. 12, 5764-5769 (2006).
47. Kosaka T, Yatabe Y, Endoh H et al.: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 64, 8919-8923 (2004).
48. Gow CH, Shih JY, Chang YL et al.: Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R. PLoS Med. 2, e269 (2005).
49. Zhou BB, Peyton M, He B et al.: Targeting ADAM mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10, 39-50 (2006).
50. Shimmura T, Lowell AM, Engelman JA et al.: Epidermal growth facior receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res. 65, 6401-6408 (2005).
51. Yang S, Qu S, Perez-Tores M et al.: Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Res. 66, 6990-6997 (2006).
52. Grbovic OM, Basso AD, Sawai A et al.: V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc. Natl Acad Sci. USA 103, 57-62 (2006).
53. Irmer D, Funk JO, Blaukat A: EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy. Oncogene DOI:10.1038/sj.onc.1210383 (2007) (Epub ahead of print).